Imaging the developing brain using light at the Pears Maudsley Centre

Imaging the developing brain using light at the Pears Maudsley Centre

Imaging the developing brain using light at the Pears Maudsley Centre

By Dr Louisa Gossé 

Brain imaging has revolutionised how we understand mental health in children and young people. It reveals that these conditions have real biological foundations and that every child’s brain is unique. Brain scans also allow us to explore how children and young people develop, and what happens in the brain when development takes an unexpected turn for example, when a child or a young person experiences a mental health condition like anxiety or depression or has a developmental condition like attention deficit hyperactivity disorder (ADHD). 

 

Can we really study the brain using light?   

One particularly exciting way to study the brain is by using light. While it may sound like something from a science-fiction film, the way it works is probably more familiar to you than it might at first seem. In the same way that a fitness watch uses light to measure heart rate, scientists can use light to measure brain activity. This method is called functional near-infrared spectroscopy, or fNIRS. It allows us to observe how the brain functions while children take part in everyday activities, rather than only when they are lying still in a scanner. 

 

How does this light-based brain imaging actually work?  

Children simply wear a soft, comfortable hat (a bit like a swimming cap) with small sensors that shine harmless near-infrared light onto the head.  

Our brains need oxygen to do its work. Whenever we do something, like listening to music or solving a puzzle, certain brain regions work harder than others and then and use more oxygen than others. The body responds by increasing blood flow to those areas of the brain. Blood that carries a lot of oxygen absorbs light differently from blood with less oxygen and the fNIRS hat picks up on these subtle changes to map brain activity. By measuring how much of the light travels through the head and is absorbed at any given time, scientists can see which areas of the brain are active and how that activity shifts over time. 

 

Why can fNIRS be such a game-changer for studying the brain during development? 

fNIRS is one of the newest, most flexible brain-imaging tools available. Unlike many traditional brain-imaging methods, fNIRS is quiet, non-invasive and highly flexible. MRI scanners, for example, have greatly advanced our understanding of the (developing) brain, but they require people to lie still inside a noisy, enclosed space. This can be challenging or overwhelming for many children and young people, especially very young children, children with different sensory needs or those with neurodevelopmental conditions like ADHD. fNIRS lets children move more freely and behave more naturally. This opens the door to research that is more inclusive, allowing more children to participate in science studies.  This movement-friendly design also makes fNIRS very valuable for understanding behaviour in real-world situations. Researchers can observe children while they chat with their parents, explore toys, solve age-appropriate tasks or even play together. Or we can study two young people wearing fNIRS hats at the same time, allowing us to understand how the developing brain works in real-life communication. This kind of natural, real-time data is extremely difficult to gather using traditional brain imaging method.

 

How will fNIRS help us improve mental health care for young people?  

We are already using fNIRS in our research within the King’s Maudsley Partnership and will continue to grow its use when the Pears Maudsley Centre for Children and Young People opens next year. Enabling children who would have otherwise been excluded from participating in research to take part is central to ensuring our work will be more likely to benefit all children, not just the easiest to study. fNIRS is an example of how we are centering inclusion and equity in our research. 

Once our understanding of the developing brain in the real-world has improved we can then work as the King’s Maudsley Partnership, on bringing it into therapeutic settings / the clinic.  

We hope that fNIRS will become a key tool for advancing our mission to improve mental health care. For example, by helping us design interventions that are tailored to an individual child or young person’s specific strengths and challenges. Or by helping clinicians with choosing the most effective treatment plan, so that we can get care and support to families faster and more efficiently. 

We also hope that brain imaging studies can then not only take place in the dedicated clinical research facilities but also in school or community settings, and even in the comfort of your homes. Our goal is to make science work for and with every child and young person, so that they can thrive to the best of their ability.  

If you want to learn more about fNIRs and our work in this area please contact us on KMPCYP@slam.nhs.uk. Learn more about the Pears Maudsley Centre.

Learn more about Dr Louisa Gosse and her work.

Follow Us

For the latest updates and news, follow us on our social channels.

Response to announcement of independent review into mental health, ADHD and autism services

Response to announcement of independent review into mental health, ADHD and autism services

Response to announcement of independent review into mental health, ADHD and autism services

A photo of Philip Shaw stood in front of the Pears Maudsley Centre for children and young people

Yesterday (4 December) the Government launched an independent review to look at rising demand for mental health, ADHD, and autism services and what is driving it.

 

Our Reaction

 

“Waiting lists for the assessment of both mental health conditions, ADHD, and autism have all risen exceptionally sharply in the last decade. Many people are seeking help from services that are stretched too thin, and people in need are falling through the cracks. 

“In order to confront this situation, we need to have a clear grasp as to why so many people are seeking help. The King’s Maudsley Partnership is home to the world’s largest group of researchers and clinicians dedicated to understanding and improving outcomes for children with a range of conditions, and we’re working hard to understand the underlying causes in an effort to provide the knowledge needed for more effective interventions. 

“The announcement of this review is a welcome one, and we hope our work will contribute meaningfully to it.” 

Follow Us

For the latest updates and news, follow us on our social channels.

RE-STAR Team & Dr Gonzalo Salazar de Pablo win at Association for Child and Adolescent Mental Health Awards

RE-STAR Team & Dr Gonzalo Salazar de Pablo win at Association for Child and Adolescent Mental Health Awards

RE-STAR Team & Dr Gonzalo Salazar de Pablo win at Association for Child and Adolescent Mental Health Awards

RE-STAR Team

Held annually, the Association for Child and Adolescent Mental Health (ACAMH) Awards aim to recognise high quality work in evidence based science, both in publication and practice, in the field of child and adolescent mental health. Receiving a nomination is prestigious recognition of work that is at the forefront of the advancement of child and adolescent mental health research, and clinical practice. 

Dr Gonzalo Salazar De Pablo wins Kathy Sylva ‘Rising Star’ Award

The Kathy Sylva ‘Rising Star’ Award is presented to someone who has made a significant scientific contribution to child and adolescent mental health literature, within 10 years of their first peer reviewed journal publication.

The 2025 Award was presented to Dr Gonzalo Salazar de Pablo, Senior Clinical Lecturer in the Department of Child & Adolescent Psychiatry, honorary Consultant Child & Adolescent Psychiatrist at the South London and Maudsley NHS Foundation Trust and part of the King’s Maudsley Partnership for Children & Young People. It was presented in recognition of his outstanding scientific contributions to child and adolescent mental health.

I am deeply honoured to receive the Kathy Sylva Rising Star Award. This recognition means a great deal to me, and it is only possible thanks to the young people, families, and colleagues I have had the privilege of working with. I am really grateful to ACAMH for this award, and to my collaborators across King’s, South London and Maudsley, and our international partners for their support and inspiration.

Dr Gonzalo Salazar de Pablo

Dr Gonzalo Salazar de Pablo’s research focuses on the early identification and prediction of bipolar disorder and psychosis in young people, advancing the field through high-impact publications.

The nomination highlighted his exceptional productivity, international collaborations, and leadership. A defining feature of Dr Salazar de Pablo’s work is his commitment to co-production with young people, families, and clinicians, ensuring that research questions and interventions are grounded in lived experience and real-world clinical needs. Receiving this award is a meaningful recognition of his work and his contributions to child and adolescent mental health.

Looking ahead, he hopes to continue developing equitable, accessible, and youth-informed approaches that improve early intervention and long-term outcomes for children and adolescents worldwide.

Lionel Hersov Memorial Award presented to RE-STAR

The Lionel Hersov Memorial Award is given to a practice or research team that has either demonstrated the translation of an evidence base into clinical practice with measurable clinical impact, or demonstrated quality improvement within either clinical or research practice.

This year, it was presented to RE-STAR Academic Researchers (Ars) and its Youth Researcher Panel (Y-RP), a four-year interdisciplinary programme led by researchers from the Department of Child & Adolescent Psychiatry, and part of the King’s Maudsley Partnership at King’s College London with UCL, Anna Freud and Centre.

We are thrilled that the work of the RE-STAR Team – both the academics and the youth researchers – has been recognised in this way. This collaborative process has been transformative on so many levels, both for those involved and the science we’ve been focused on. Ultimately, we hope this will help us find new ways to promote the mental health of neurodivergent young people.

Dr Susie Chandler

RE-STAR Programme Manager, Department of Child & Adolescent Psychiatry, IoPPN

RE-STAR, led by Professor Edmund Sonunga-Barke, explores the interplay between autism and/or ADHD traits, exposure to environmental stressors, and emotional responding in neurodivergent young people, in driving developmental pathways to depression.

Who are the RE-STARs? To me we are a band of neurodiverse adventurer scientists coming together, at a particular moment in time, to explore new ways of doing child and adolescent mental health research by stretching the boundaries of participatory and inter-disciplinary practice. I believe our last four years of work illustrates the creative energy that can be released when researchers from radically different backgrounds come together with young autistic young people and those with ADHD to produce real progress in ideas new, methods, interpretations and interventions.

Professor Edmund Sonuga-Barke

RE-STAR Chief Investigator, Department of Child & Adolescent Psychiatry, IoPPN

The programme works closely with its Youth Researcher Panel, who play an integral role in the planning and delivery of RE-STAR, and contribute to the project in a wide variety of ways, working alongside the academic researchers as ‘co-researchers’, co-analysing and collecting data, and helping to share and communicate the work of RE-STAR to a wider audience.

RE-STAR is funded by UKRI Medical Research Council.

Celebrating the award wins, Head of Department for Child & Adolescent Psychiatry, Professor Philip Shaw, said, “I know that all in the King’s Maudsley Partnership join me in congratulating the award winners and those nominated, and a shout out also to others at KMP who were nominated, the awardees showcase how King’s Maudsley Partnership strives to infuse research into clinical care, and will enrich our research through clinical insights and experience.”

Dr Gonzalo Salazar de Pablo, the Rising Star, has provided consistently highly impactful reviews of studies that centre on key clinical questions.  His achievement is all the more impressive as he is very active in CAMHS, both working with families and developing care pathways.  The RE-STAR team, led by Professor Sonuga-Barke, gain their award in part for placing neurodivergent young people at the core of all of stages of their research.  In RE-STAR, experts by lived experience and experts by academic training have together provided rich insights into why depression is so often experienced by neurodivergent youth.  

Professor Philip Shaw

Director of the King’s Maudsley Partnership and Head of Department of Child & Adolescent Psychiatry, IoPPN

Alongside these wins, we’re delighted to recognise Dr. Josefien Breedvelt who was also nominated for the Rising Star award, and Mr Sangwoo Richard Jung, shortlisted for Clinical Trainee of the Year.

Follow Us

For the latest updates and news, follow us on our social channels.

Prestigious Academy of Medical Sciences Professorship awarded to Professor Philip Shaw

Prestigious Academy of Medical Sciences Professorship awarded to Professor Philip Shaw

Prestigious Academy of Medical Sciences Professorship awarded to Professor Philip Shaw

A photo of Philip Shaw stood in front of the Pears Maudsley Centre for children and young people

Professor Philip Shaw, Head of Child and Adolescent Psychiatry at King’s College London and Director of the King’s Maudsley Partnership for Children and Young People, has been awarded a prestigious Professorship by the Academy of Medical Sciences (AMS).

Philip joined King’s from the US National Institutes of Health in 2024 to become Head of Child and Adolescent Psychiatry at King’s College London and take up the position of Director of the King’s Maudsley Partnership for Children and Young People.

Philip’s research focuses on understanding the life course of symptoms of Attention Deficit Hyperactivity Disorder (ADHD) and related conditions. Working alongside those living with ADHD, he looks at how differences in the brain, alongside the genetic and the environmental factors together impact on symptoms as children grow into adulthood. The AMS professorship will help Philip and his team use ‘Big Data’ to gain further insights into the reasons why some children ‘grow out’ of ADHD, whereas others have persistent challenges. The award will also help his team build links with local communities, ensuring that clinical research both reflects the voice of those with lived experience and captures the rich diversity of its south London home. His ultimate aim is to translate these discoveries into new tools to help better target existing treatments and as the foundation of new interventions. His clinical work as a consultant psychiatrist in specialist NHS child and adolescent mental health services, both inspires and shapes his research.

I’m honoured to be recognised by the Academy of Medical Sciences through this Professorship. The award will enable my team to use large-scale data to understand why some children ‘grow out’ of ADHD while others continue to face challenges into adulthood, and to translate those insights into more precise, effective interventions. Having recently joined the UK research community, I’m excited to be part of such a collaborative and internationally connected environment that values global perspectives in improving children’s and young people’s mental health.

Professor Philip Shaw

The Academy of Medical Sciences Professorship scheme is designed to attract and retain outstanding emerging leaders from around the world, strengthening the UK’s biomedical research landscape. Supported by the Department for Science, Innovation and Technology, the initiative provides flexible funding to individuals either newly appointed to or about to begin full Professorships.

The Academy of Medical Sciences (AMS) Professorship is a highly prestigious award and undergoes a rigorous selection process. I am delighted Philip has received this award, which is a reflection of his international standing in children and young people’s mental health research and will allow him to expand his research and its impact, through the King’s Maudsley Partnership.

Professor Matthew Hotopf, Executive Dean, IoPPN

 

 

“I congratulate Professor Philip Shaw on receiving this prestigious award. His work is already driving forward discoveries and innovation in children’s mental health and neurodivergence, and we’re excited to see how this recognition will further support his innovative research and its real-world applications including through the delivery of services in South London.”

David Bradley, Chief Executive South London and Maudsley NHS Trust

Follow Us

For the latest updates and news, follow us on our social channels.

Experts come together to discuss ADHD research and treatments

Experts come together to discuss ADHD research and treatments

Experts come together to discuss ADHD research and treatments

Leading experts explored what Attention Deficit Hyperactivity Disorder (ADHD) is, how it affects children and young people and what research questions are currently under investigation.

The “ADHD: New Discoveries, Better Support” webinar, held on Tuesday 4 November, brought together clinicians, researchers and experts by lived experience to reflect on the clinical academic research taking place on ADHD. The King’s Maudsley Partnership is home to the world’s largest group of researchers and clinicians dedicated to understanding and improving outcomes for children with ADHD.

Professor Philip Shaw, Director of the King’s Maudsley Partnership for Children and Young People, who’s academic work is focused on ADHD, chaired the webinar.

The focus of the work on ADHD across the King’s Maudsley Partnership is to develop new and better treatments for ADHD to give children, young people and families greater choice.

Professor Philip Shaw

Director of King's Maudsley Partnership

Increasing choice and quality of treatments 

In recent years awareness and understanding of ADHD have increased, however the treatment and support options available to support children and young people with ADHD have not kept pace. Most treatments are medication-based, and while these can be effective, many families and young people want more choices — especially non-drug alternatives.

These thoughts were echoed by Tiegan Boyens a neurodivergent lived experience consultant who joined the panel. She reflected that it took her a long time to get an ADHD diagnosis due to misconceptions around ADHD such as that it manifests primarily in physical activity and in boys. She called on researchers to do more to investigate supporting children who have ADHD alongside other comorbidities. She also said she wants to see more non-drug based treatment options to be available.

Research has helped me embark on my own journey and gain a deeper understanding of neurodiversity, both generally and personally.

Tiegan Boyens

Youth Research Panel Member for RE-STAR (Regulating Emotions – Strengthening Adolescent Resilience)

Novel brain therapies 

Professor Katya Rubia is focused on pioneering non-drug treatments for children and adults with ADHD. She spoke about some of the recent discoveries in this area. She has been investigating non-invasive brain stimulation to see if these can mimic the effects of ADHD medication by targeting the same brain regions, but without the side effects of drugs. She shared promising findings using transcranial direct current stimulation in children and adults with ADHD and new findings around Trigeminal nerve stimulation (TNS) which are due for publication in Nature Medicine in the coming weeks. She also reflected on the challenges of the placebo effect in studies involving cutting edge technology.

High-technology brain therapies have more than twice the placebo effect compared placebo effects in drug studies. Therefore, it is crucial to control the placebo effect in brain therapies so that patients do not spend thousands of dollars on treatments that do not work and give them false hope.

Professor Katya Rubia

Professor of Cognitive Neuroscience, King's College London

More information on the ATTENS (ADHD trial of external trigeminal nerve stimulation) project can be found here: ATTENS 

Tools to support children’s sleep 

Almost 75% of children with ADHD have sleep problems. Parents and carers report that poor sleep makes their children’s daytime behaviour and schoolwork worse and affects the quality of life of the whole family. However there are limited options for support and medication is the most common intervention. Professor Samuele Cortese provided insight into the DISCA (Digital Sleep Support for Children with ADHD) study. This research project aims to help parents, carers, and health professionals to manage sleep problems in children with ADHD.

Medication should not be the first line of treatment for insomnia in children with ADHD yet behavioural interventions are not routinely available in the NHS. We have developed the first digital intervention of its kind to be tested in the UK for children with ADHD who experience sleep problems, and we are testing it in a trial. Parents/carers of children with ADHD and sleep problems will be offered this intervention for free if they take part in the study

Professor Samuele Coretese

NIHR Research Professor of Child and Adolescent Psychiatry at the University of Southampton

More information about DISCA including information on how families can sign up to get involved in the study can be found at Home | Disca Study 

How data is guiding our work 

Professor Johnny Downs who leads the CAMHS Digital Lab shared data around children with ADHD living in south London. The data tells us that early childhood factors and demographics including ethnicity and gender make an ADHD diagnosis more likely even though this doesn’t represent true prevalence. He found that children from non-white ethnic groups are almost 50% less likely to get a diagnosis. He reflected that services need to ensure they are engaging effectively with all local communities to ensure all children who need it can access support services for ADHD.  

Professor Downs also reflected the ambitions of the CAMHS Digital Lab to continue to build digital tools to support parents and carers whose child is on the waiting list, or who has received a diagnosis, for ADHD. This follows successful outcomes from providing digital support to parents and carers on the waiting list for services via the My Health-E app. There is a virtuous circle that parents and carers receive more support and guidance whilst on the waiting list and their participation helps build a richer bank of data to underpin research into ADHD.

The challenge for us is to use data in a way that helps people in clinics—clinicians, young people, and families—and to determine how we can use this data to make real changes in their daily lives and in the factors that might affect their treatment

Professor Johnny Downs

Leader of CAMHS Digital Lab and Professor of Child Psychiatry and Health Informatics

More information on the CAMHS Digital Lab can be found on its website Home | CAMHS Digital Lab 

The webinar came just after ADHD Awareness Month, throughout which the King’s Maudsley Partnership has been highlighting it’s work on ADHD. The King’s Maudsley Partnership’s home will be in the Pears Maudsley Centre for Children and Young People, due to open in 2026. The Centre will have a one of it’s kind research facility enabling us to revolutionise our understanding ADHD and other neurodevelopmental conditions, and mental health conditions that affect children and young people.

For more information, please contact Helen Honstvet on helen.honstvet@slam.nhs.uk or sign up to our newsletter to keep up to date with the work happening across the Partnership. You can also watch the recording of the webinar on our YouTube channel.

Follow Us

For the latest updates and news, follow us on our social channels.